Levetiracetam Neuraxpharm

Levetiracetam, the active ingredient in Levetiracetam Neuraxpharm, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset, myoclonic and primary generalized tonic‑clonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an anticonvulsant that reduces abnormal neuronal firing in various seizure types. - Partial‑onset seizures: helps achieve seizure control in focal epilepsy. - Myoclonic seizures: reduces frequency and severity of sudden muscle jerks. - Primary generalized tonic‑clonic seizures: lowers the occurrence of convulsive episodes across the brain.

Levetiracetam may cause a range of adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness or lack of energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin blistering. - Blood dyscrasias: abnormal blood cell counts. - Suicidal thoughts: new or worsening depression. - Severe skin rash: including toxic epidermal necrolysis. - Hepatic failure: signs of liver dysfunction.

Before prescribing Levetiracetam, consider the following safety measures. - Renal impairment: adjust dose based on kidney function. - Hepatic impairment: monitor liver enzymes regularly. - Pregnancy: risk unknown; weigh benefits against potential risks. - Concomitant CNS depressants: may enhance sedation. - Psychiatric disorders: monitor for mood changes or depression. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam levels. - Phenytoin: reduces efficacy of levetiracetam. - Phenobarbital: may decrease seizure control. - Rifampin: strong inducer that lowers drug concentration. - St. John's wort: herbal inducer that reduces exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam plasma levels. - Topiramate: combined CNS effects may increase dizziness. - Zonisamide: additive seizure‑control effects require observation. - Alcohol: enhances sedative properties. - Sedative hypnotics: may cause excessive drowsiness.